Can I Take Folate with Crestor (Rosuvastatin)?

The Short Answer: Folate Is Safe to Take with Crestor

No primary pharmacokinetic interaction exists between folate (in any of its common forms) and rosuvastatin. The two compounds are metabolized through completely separate pathways, and co-administration does not alter the plasma concentration of either drug in a clinically meaningful way. Routine dose separation is not required by any current guideline from the FDA, the American College of Cardiology, or the American Heart Association.

The story is not entirely simple. Rosuvastatin is prescribed because cardiovascular risk is already elevated. Folate influences homocysteine metabolism, and homocysteine is an independent marker of cardiovascular disease. Understanding how these two intersect is worth your time, particularly if you carry an MTHFR variant or have borderline renal function.

How Rosuvastatin Is Processed by the Body

Rosuvastatin is absorbed in the small intestine and reaches peak plasma concentration in roughly 3 to 5 hours. Its primary hepatic uptake depends on the organic anion transporting polypeptide OATP1B1 (encoded by SLCO1B1) and the efflux transporter BCRP (encoded by ABCG2). Cytochrome P450 metabolism is minimal: CYP2C9 accounts for only about 10% of its metabolism, and CYP3A4 plays almost no role [1].

This transporter-dominant profile is why drug interactions with rosuvastatin are often transporter-based rather than enzyme-based. Cyclosporine, for example, inhibits OATP1B1 and raises rosuvastatin AUC by up to 7-fold, triggering a contraindication [2]. Folate does not inhibit OATP1B1, BCRP, or CYP2C9 at any physiologic or supplemental dose studied to date.

How Folate Is Processed by the Body

Dietary folate and supplemental folic acid travel distinct absorption routes. Dietary polyglutamate folates are hydrolyzed in the jejunum to monoglutamates before entering circulation. Synthetic folic acid is already a monoglutamate and is absorbed more efficiently, but it requires conversion to dihydrofolate (DHF) and then to 5-methyltetrahydrofolate (5-MTHF) via the MTHFR enzyme before it can donate methyl groups [3].

5-MTHF donates its methyl group to homocysteine, converting it to methionine in a reaction requiring vitamin B12 as cofactor. This entire pathway is cytoplasmic and mitochondrial. It does not share enzymes with the statin biosynthetic pathway, so co-administration creates no competition for the same metabolic machinery.

MTHFR Variants: Why Your Genetic Profile Changes the Conversation

Roughly 10 to 15% of people of Northern European ancestry carry two copies of the MTHFR C677T variant (homozygous TT genotype), which reduces MTHFR enzyme activity by approximately 70% compared to the wild-type CC genotype [4]. An additional 40 to 45% carry one copy (heterozygous CT), with roughly 35% reduced activity.

What Reduced MTHFR Activity Means for Folate Supplementation

When MTHFR activity is reduced, supplemental folic acid accumulates as unmetabolized folic acid (UMFA) in plasma rather than converting efficiently to 5-MTHF. UMFA has no established methyl-donor function and some observational data suggest high levels may mask B12 deficiency or, in specific contexts, influence cancer surveillance mechanisms [5]. For this reason, many clinicians who specialize in nutrigenomics recommend that MTHFR TT carriers use 5-MTHF (sold as Deplin at prescription doses, or over-the-counter at 400 to 1,000 mcg) rather than standard folic acid.

Does MTHFR Status Affect Rosuvastatin Efficacy?

No published trial shows that MTHFR genotype alters rosuvastatin's LDL-lowering efficacy. Rosuvastatin inhibits HMG-CoA reductase, an enzyme in the mevalonate pathway that sits entirely upstream of the folate-methionine cycle. Genetic variability in folate metabolism does not feed back into the mevalonate pathway in any mechanistically established way.

A practical decision framework used by the HealthRX medical team categorizes patients on rosuvastatin into three groups before recommending a folate form:

Group 1 (No known MTHFR variant, standard cardiovascular risk): Standard folic acid 400 mcg/day is appropriate. No special timing relative to rosuvastatin is needed.

Group 2 (Heterozygous CT or homozygous TT, or untested but with elevated homocysteine >10 micromol/L): Prefer 5-MTHF 400 to 800 mcg/day. Recheck homocysteine and B12 at 3 months.

Group 3 (Homozygous TT with fasting homocysteine >15 micromol/L, or concurrent renal impairment): Prescriber-supervised dosing of 5-MTHF up to 1,000 mcg/day alongside B12 800 to 1,000 mcg/day. Renal function monitoring every 6 months.

Homocysteine, Cardiovascular Risk, and the Folate Connection

Elevated plasma homocysteine is associated with increased ASCVD risk. A meta-analysis published in the BMJ (N=approximately 30,000 participants pooled across 30 studies) found that each 5 micromol/L rise in homocysteine was associated with a 20% higher risk of coronary artery disease events, independent of traditional risk factors [6].

Does Lowering Homocysteine with Folate Reduce Events on Top of a Statin?

This is where the data get genuinely complex. The HOPE-2 trial randomized 5,522 adults with established vascular disease to daily folic acid 2.5 mg plus B6 50 mg plus B12 1 mg versus placebo. After 5 years, homocysteine fell 25% in the active arm, but the composite cardiovascular endpoint was not significantly reduced (relative risk 0.95, 95% CI 0.84 to 1.07) [7]. Most participants in HOPE-2 were not on intensive statin therapy.

The SEARCH trial (N=12,064) examined high-dose folic acid supplementation in patients predominantly on simvastatin. After 6.7 years, no reduction in major vascular events occurred despite a 28% homocysteine reduction [8]. This raises the important question of whether lowering homocysteine as a target, independent of treating the underlying inflammatory or endothelial mechanisms, translates to meaningful benefit when background cardiovascular therapy is already in place.

What This Means Practically for Rosuvastatin Patients

Rosuvastatin already addresses LDL-C, the primary driver of atherosclerotic plaque progression. Folate supplementation is not a replacement for statin therapy, and adding folate specifically to lower cardiovascular risk beyond what rosuvastatin provides is not supported by current randomized trial evidence. Where folate supplementation remains clearly indicated is in pregnancy (to prevent neural tube defects), in patients with dietary deficiency, and in those taking medications that deplete folate stores.

Medications That Deplete Folate and How This Intersects with Statin Therapy

Several drug classes reduce folate levels, and patients on these agents are sometimes also prescribed rosuvastatin for cardiovascular risk reduction. Understanding which drugs impair folate metabolism is clinically relevant.

Anticonvulsants

Phenytoin, carbamazepine, valproate, and primidone all reduce serum folate through a combination of intestinal absorption impairment and increased hepatic metabolism of folate. A review in Epilepsia noted that up to 91% of patients on long-term phenytoin therapy had suboptimal folate levels [9]. Patients on anticonvulsants who are also prescribed rosuvastatin should have baseline folate and homocysteine checked and may need supplementation at 1 mg/day of folic acid (or equivalent 5-MTHF).

Methotrexate and Sulfasalazine

Both drugs inhibit dihydrofolate reductase (DHFR), and both are used in autoimmune diseases that carry elevated cardiovascular risk, making statin co-prescription common. The ACR and EULAR guidelines specifically recommend 5 mg folic acid once weekly (or 1 mg daily) for patients on methotrexate to reduce mucosal and hematologic toxicity [10]. Rosuvastatin does not interfere with this protective supplementation protocol.

Proton Pump Inhibitors (PPIs)

Long-term PPI use reduces gastric acid and may impair folate absorption by altering the pH-dependent uptake in the proximal small intestine. Many patients on rosuvastatin also take a PPI for GI symptoms exacerbated by aspirin or other antiplatelet agents. Monitoring folate annually in this scenario is reasonable, though no randomized trial has established that PPI-associated folate decline reaches clinical deficiency thresholds in the absence of other risk factors.

Monitoring Parameters When Taking Both

No guideline requires additional laboratory monitoring solely because a patient is taking folate alongside rosuvastatin. Standard rosuvastatin monitoring includes a lipid panel at 4 to 12 weeks after initiation or dose change, and annual lipid panels thereafter, along with liver enzymes if symptoms arise [11].

If a clinician has reason to assess folate status (MTHFR variant suspicion, methotrexate use, anticonvulsant co-therapy, or dietary concern), the relevant labs are:

• Serum folate (reflects recent intake; normal roughly 2.7 to 17 ng/mL)
• Red blood cell (RBC) folate (reflects 90-day average status; normal roughly 140 to 628 ng/mL)
• Plasma homocysteine (fasting; optimal <10 micromol/L, elevated >15 micromol/L)
• Serum B12 (to rule out co-deficiency masking before starting high-dose folate)

Rosuvastatin does not alter any of these markers directly. Conversely, folate supplementation does not alter the lipid-panel results produced by rosuvastatin.

Dose and Timing Recommendations

Standard Adult Folate Dosing

The Recommended Dietary Allowance (RDA) for folate in non-pregnant adults is 400 mcg of dietary folate equivalents (DFE) per day, rising to 600 mcg DFE during pregnancy [12]. Supplemental folic acid is roughly 1.7-fold more bioavailable than food folate when taken with food, and roughly 2-fold more bioavailable when taken fasted.

For most adults on rosuvastatin with no specific folate-depleting drugs, a multivitamin containing 400 mcg folic acid is nutritionally adequate. There is no basis in the current literature for taking higher doses to "boost" statin efficacy.

Timing Relative to Rosuvastatin

Rosuvastatin is commonly taken in the evening, though it can be taken at any time of day. No pharmacokinetic study has identified a time-sensitive window that must be respected between folate ingestion and rosuvastatin ingestion. Patients can take both at the same time without concern.

High-Dose Folate (Greater Than 1 mg/Day)

Doses above 1 mg/day require a prescription in some countries and warrant physician oversight for two reasons. First, high-dose folic acid can mask the megaloblastic anemia of vitamin B12 deficiency without correcting the neurological damage, delaying a critical diagnosis [13]. Second, observational data from the Nurses' Health Study and SELECT trial raised questions about whether very high folic acid intakes accelerate progression of pre-existing colorectal adenomas in specific populations, though this remains an area of active research rather than settled science [5].

Pharmacist and Prescriber Communication Tips

The American Heart Association's 2019 statement on dietary supplements and cardiovascular disease notes that "most commonly used dietary supplements have not been shown to reduce cardiovascular events in RCTs," and recommends that clinicians take a "routine inventory of all supplements" during each visit [14].

Telling your pharmacist or prescriber that you take folate takes about 15 seconds and enables accurate medication reconciliation. Bring the supplement bottle (or a photo of the label) so the dose and form are recorded accurately, since "folate" on a patient's self-report can mean anything from 200 mcg folic acid in a multivitamin to 15 mg of prescription L-methylfolate.

Special Populations

Pregnancy and Preconception

Women of childbearing age on rosuvastatin face a different calculus. Rosuvastatin is FDA Pregnancy Category X (contraindicated in pregnancy) because statins impair fetal cholesterol biosynthesis [2]. Any woman planning pregnancy should discuss stopping rosuvastatin with her prescriber before conception. Preconception folate supplementation (400 to 800 mcg/day) remains recommended by the USPSTF to reduce neural tube defect risk, and this supplementation is entirely compatible with rosuvastatin use during the pre-pregnancy interval when rosuvastatin has not yet been discontinued.

Chronic Kidney Disease (CKD)

Rosuvastatin dose is capped at 10 mg/day in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) because renal clearance contributes to elimination [2]. Folate itself is water-soluble and renally cleared; patients with CKD can accumulate homocysteine partly because impaired renal function reduces conversion of homocysteine to cystathionine. Folate supplementation in CKD is often used to address this, but large RCTs including the HOST trial (N=2,056, CKD patients randomized to high-dose B-vitamins including folic acid 40 mg/day) did not demonstrate reduced cardiovascular events or slowed kidney function decline [15]. Standard-dose folate (400 mcg/day) in CKD patients on rosuvastatin remains reasonable and safe.

Older Adults

Folate absorption may decrease modestly with age due to reduced gastric acid secretion and altered intestinal motility. Older adults on rosuvastatin who eat a varied diet with legumes, leafy greens, and fortified grains are unlikely to be deficient. Those with restricted diets, malabsorption syndromes, or polypharmacy (multiple folate-depleting agents) benefit from laboratory confirmation before supplementing at high doses.